Patents Examined by Karen Cochrane Carlson
  • Patent number: 10077453
    Abstract: Some aspects of this disclosure provide compositions, methods, systems, and kits for controlling the activity of RNA-programmable endonucleases, such as Cas9, or for controlling the activity of proteins comprising a Cas9 variant fused to a functional effector domain, such as a nuclease, nickase, recombinase, deaminase, transcriptional activator, transcriptional repressor, or epigenetic modifying domain. For example, the inventive proteins provided comprise a ligand-dependent intein, the presence of which inhibits one or more activities of the protein (e.g., gRNA binding, enzymatic activity, target DNA binding). The binding of a ligand to the intein results in self-excision of the intein, restoring the activity of the protein.
    Type: Grant
    Filed: July 30, 2015
    Date of Patent: September 18, 2018
    Assignee: President and Fellows of Harvard College
    Inventors: David R. Liu, Kevin Davis
  • Patent number: 10076574
    Abstract: Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject.
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: September 18, 2018
    Assignee: Wayne State University
    Inventors: Jianjun Wang, Qianqian Li, Michael Chopp, Feng Jiang, Guojun Wu
  • Patent number: 10072276
    Abstract: Provided is a genetically engineered yeast cell having increased NADPH production, a method of increasing a NADPH level in a yeast cell, a method of preparing the genetically engineered yeast cell, and a method of producing lactate using the genetically engineered yeast cell.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: September 11, 2018
    Assignee: SAMSUNG ELECTRONICS CO., LTD.
    Inventors: Yukyung Jung, Kwangmyung Cho, Jinha Kim, Soonchun Chung
  • Patent number: 10072236
    Abstract: The present invention relates to detergent compositions comprising protease variants and methods for obtaining such detergent compositions. The present invention also relates to the use of such detergent compositions, especially in laundry or in hard surface cleaning applications.
    Type: Grant
    Filed: July 28, 2014
    Date of Patent: September 11, 2018
    Assignee: Henkel AG & Co. KGaA
    Inventors: Timothy O'Connell, Susanne Tondera, Hendrik Hellmuth, Thomas Weber, Frank Winther Rasmussen, Rolf Thomas Lenhard, Miguel Duarte Guilherme Pereira Toscano, Esben Friis, Signe Eskildsen Larsen, Juergen Carsten Franz Knoetzel, Mikael Bauer
  • Patent number: 10066025
    Abstract: The invention described herein relates to the discovery that renalase, and fragments thereof, are useful for the treatment or prevention of cardiac and renal diseases or disorders. Thus, the invention relates to compositions comprising renalase, or fragments thereof, and methods for treating and preventing cardiac and renal disease or disorders.
    Type: Grant
    Filed: July 16, 2013
    Date of Patent: September 4, 2018
    Assignee: YALE UNIVERSITY
    Inventor: Gary Desir
  • Patent number: 10059754
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise the addition of glucocorticoid compound during the culturing period. The addition of glucocorticoid compound sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: August 28, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ying Jing, Zhengjian Li, Yueming Qian
  • Patent number: 10052367
    Abstract: The present invention includes compositions and methods for treating disease and disorders associated with pathological calcification or pathological ossification by modulating the level or activity of NPP1 or a mutant thereof, or a mutant NPP4 modified to exhibit ATP hydrolase activity similar to the hydrolase activity of NPP1.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: August 21, 2018
    Assignee: Yale University
    Inventors: Demetrios Braddock, Ronald Albright
  • Patent number: 10047383
    Abstract: The present invention provides various combinations of genetic modifications to a transformed host cell that provide increase conversion of carbon to a chemical product. The present invention also provides methods of fermentation and methods of making various chemical products.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 14, 2018
    Assignee: CARGILL, INCORPORATED
    Inventors: Hans Liao, Christopher Patrick Mercogliano, Travis Robert Wolter, Michael Tai Man Louie, Wendy Kathleen Ribble, Tanya Lipscomb, Eileen Colie Spindler, Michael Lynch
  • Patent number: 10041092
    Abstract: Provided herein are methods of integrating one or more exogenous nucleic acids into one or more selected target sites of a host cell genome. In certain embodiments, the methods comprise contacting the host cell genome with one or more integration polynucleotides comprising an exogenous nucleic acid to be integrated into a genomic target site, a nuclease capable of causing a break at the genomic target site, and a linear nucleic acid capable of homologous recombination with itself or with one or more additional linear nucleic acids contacted with the population of cells, whereupon said homologous recombination results in formation of a circular extrachromosomal nucleic acid comprising a coding sequence for a selectable marker. In some embodiments, the methods further comprise selecting a host cell that expresses the selectable marker.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: August 7, 2018
    Assignee: AMYRIS, INC.
    Inventors: Andrew Horwitz, Kristy Michelle Hawkins, Max Schubert, Wayne Szeto
  • Patent number: 10041052
    Abstract: The present invention relates to a phytase which has at least 74% identity to a phytase derived from Citrobacter braakii and comprises at least one alteration as compared to this phytase. These phytase variants have amended, preferably improved, properties, such as thermostability, temperature profile, pH profile, specific activity, performance in animal feed, reduced protease sensibility, and/or an amended glycosylation pattern. The invention also relates to DNA encoding these phytases, methods of their production, as well as the use thereof, e.g., in animal feed and animal feed additives.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: August 7, 2018
    Assignee: Novozymes A/S
    Inventors: Leonardo De Maria, Carsten Andersen, Lars Kobberoee Skov, Mikael Blom Soerensen
  • Patent number: 10036003
    Abstract: Described are alkenol dehydratase variants having improved activity in catalyzing the conversion of a compound corresponding to the general formula CnH2nO into CnH2n-2 +H2O with 3<n<7. In particular, described are alkenol dehydratase variants having, e.g., an improved activity in converting but-2-en-1-ol (crotyl alcohol) into 1,3 butadiene and/or an improved activity in converting but-3-en-2-ol into 1,3 butadiene and/or an improved activity in converting 3-methylbut-2-en-1-ol (prenol) or 3-methylbut-3-en-2-ol (isoprenol) into isoprene and/or an improved activity in converting 2,3-dimethyl-but-2-en-1-ol into dimethyl-butadiene.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: July 31, 2018
    Assignees: Global Bioenergies, Scientist of Fortune, S.A.
    Inventors: Philippe Marliere, Marc Delcourt, Sabine Mazaleyrat
  • Patent number: 10030064
    Abstract: The present invention describes methods and processes for the production of proteins, particularly glycoproteins, by animal cell or mammalian cell culture, preferably, but not limited to, fed-batch cell cultures. In one aspect, the methods comprise the addition of glucocorticoid compound during the culturing period. The addition of glucocorticoid compound sustain a high viability of the cultured cells, and can yield an increased end titer of protein product, and a high quality of protein product, as determined, e.g., by sialic acid content of the produced protein.
    Type: Grant
    Filed: December 1, 2016
    Date of Patent: July 24, 2018
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Ying Jing, Zhengjian Li, Yueming Qian
  • Patent number: 10030046
    Abstract: The present disclosure provides affinity tags, fusion proteins comprising one or more affinity tags, compositions comprising a fusion protein, methods of purifying a protein using an affinity tag, and devices for purifying a protein using an affinity tag.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: July 24, 2018
    Assignee: University of Washington
    Inventors: Francois C. Baneyx, Brandon L. Coyle
  • Patent number: 10016491
    Abstract: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: July 10, 2018
    Assignee: Halozyme, Inc.
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Patent number: 10017832
    Abstract: The present invention relates to enzymes, compositions and methods for catalyzing site specific recombination at asymmetric sites.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: July 10, 2018
    Assignee: WASHINGTON UNIVERSITY
    Inventors: James J. Havranek, Chi Zhang, Joseph C. Corbo, Connie A. Myers, Robi D. Mitra, Zongtai Qi
  • Patent number: 10017581
    Abstract: In certain embodiments, the present disclosure provides compositions and methods for treating Pompe disease.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 10, 2018
    Assignee: Valerion Therapeutics, LLC
    Inventors: Dustin D. Armstrong, Jeffrey C. Way
  • Patent number: 10001491
    Abstract: The present invention relates to a method for the in vitro determination of the radiosensitivity of a subject. More particularly, the invention relates to a method comprising a step of inducing an exogenous stress on a biological sample from a subject, followed by the comparison of the presence or level of at least one compound chosen in a group of defined compounds, in said biological sample and in a reference sample. The present invention also relates to the use of said at least one compound as predictive biomarker of the radio-sensitivity of a subject. The invention also relates to a kit for the detection of the presence or level of at least one of said compounds, usable in a method according to the invention.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: June 19, 2018
    Assignees: Centre Hospitalier Universitaire de Montpellier, Universite de Montpellier, Institut Regional du Cancer de Montpellier
    Inventors: David Azria, Jerome Lacombe, Jerome Solassol, Alain Mange
  • Patent number: 10000549
    Abstract: Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: June 19, 2018
    Assignees: KAHR Medical Ltd., Hadasit Medical Research Services and Development Ltd.
    Inventor: Michal Dranitzki Elhalel
  • Patent number: 10000758
    Abstract: Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 3-hydroxyisobutyrate or MAA. Also provided herein are methods for using such an organism to produce 3-hydroxyisobutyrate or MAA.
    Type: Grant
    Filed: April 19, 2016
    Date of Patent: June 19, 2018
    Assignee: Genomatica, Inc.
    Inventors: Anthony P. Burgard, Robin E. Osterhout, Stephen J. Van Dien, Cara Ann Tracewell, Priti Pharkya, Stefan Andrae
  • Patent number: 9976129
    Abstract: A fusion protein for protein detection in which are fused: a protein domain including at least one among a C1 domain of protein G, a C2 domain of protein G, and a C3 domain of protein G; and a double mutant D153G/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 153 amino acid residue Asp has been substituted by Gly and the 330 amino acid residue Asp has been substituted by Asn, a double mutant D153H/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 153 amino acid residue Asp has been substituted by His and the 330 amino acid residue Asp has been substituted by Asn, or a double mutant K328R/D330N of Escherichia coli alkaline phosphatase (BAP) in which the 328 amino acid residue Lys has been substituted by Arg and the 330 amino acid residue Asp has been substituted by Asn.
    Type: Grant
    Filed: October 6, 2014
    Date of Patent: May 22, 2018
    Assignees: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, Hitachi, Ltd.
    Inventors: Noriho Kamiya, Kyoichi Matsuba, Kenji Nagai, Kounosuke Hayashi